7:02 PM
 | 
Sep 25, 2008
 |  BC Extra  |  Company News

MorphoSys exercises antibody option

MorphoSys (Xetra:MOR) exercised its first option to participate in development of an antibody under its 2007 deal with Novartis (NYSE:NVS; SWX:NOVN). The antibody's target and intended indication are undisclosed....

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >